Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chester Li

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of the American Chemical Society|October 14, 2004
Engineered protein cages for nanomaterial synthesisRyan M Kramer, Chester Li, Daniel C Carter, et al.
Acta Crystallographica. Section D, Biological Crystallography|June 23, 2006
Structure of human ferritin L chainZhongmin Wang, Chester Li, Melanie Ellenburg, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 25, 2002
Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry diseaseChester Li, Robin J Ziegler, Maribeth Cherry, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 10, 2017
Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8-mediated Hepatic Expression of α-galactosidase ARobin J Ziegler, Maribeth Cherry, Christine M Barbon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 28, 2006
Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase ARobin J Ziegler, Maribeth Cherry, Christine M Barbon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 16, 2005
AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick diseaseChristine M Barbon, Robin J Ziegler, Chester Li, et al.
Human Gene Therapy|May 29, 2002
Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry diseaseRobin J Ziegler, Chester Li, Maribeth Cherry, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2004
AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry miceRobin J Ziegler, Scott M Lonning, Donna Armentano, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of the American Chemical Society|October 14, 2004
Engineered protein cages for nanomaterial synthesisRyan M Kramer, Chester Li, Daniel C Carter, et al.
Acta Crystallographica. Section D, Biological Crystallography|June 23, 2006
Structure of human ferritin L chainZhongmin Wang, Chester Li, Melanie Ellenburg, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 25, 2002
Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry diseaseChester Li, Robin J Ziegler, Maribeth Cherry, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 10, 2017
Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8-mediated Hepatic Expression of α-galactosidase ARobin J Ziegler, Maribeth Cherry, Christine M Barbon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 28, 2006
Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase ARobin J Ziegler, Maribeth Cherry, Christine M Barbon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 16, 2005
AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick diseaseChristine M Barbon, Robin J Ziegler, Chester Li, et al.
Human Gene Therapy|May 29, 2002
Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry diseaseRobin J Ziegler, Chester Li, Maribeth Cherry, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2004
AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry miceRobin J Ziegler, Scott M Lonning, Donna Armentano, et al.
Pageof 1